Study details
Enrolling now
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
EpicentRx, Inc.
NCT IDNCT04673942ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
140
Study length
about 5.9 years
Ages
18+
Locations
6 sites in CA, OH, TX
What this study is about
Researchers are testing the safety and tolerability of AdAPT-001, an oncolytic virus. The trial also aims to determine if AdAPT-001 is effective when used alone or with a checkpoint inhibitor.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive AdAPT-001
- 2.Take Checkpoint Inhibitor, Immune
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Dose Limiting Toxicities (DLT), Maximum tolerated dose
Secondary: Objective response rate
Body systems
Oncology